The Misuse of Drugs (Amendment No.2) Regulations (Northern Ireland) 2010
In accordance with section 31(3) of that Act, it has consulted with the Advisory Council on the Misuse of Drugs.
Citation and commencement
1.
These Regulations may be cited as the Misuse of Drugs (Amendment No.2) Regulations (Northern Ireland) 2010 and shall come into operation on 23rd July 2010.
Interpretation
2.
(1)
(2)
Amendment to the 2002 Regulations
3.
The 2002 Regulations shall be amended as follows.
4.
“(n)
Any compound structurally derived from 2-aminopropan-1–one by substitution at the 1-position with any monocyclic, or fused-polycyclic ring system (not being a phenyl ring or alkylenedioxyphenyl ring system), whether or not the compound is further modified in any of the following ways, that is to say—
(i)
by substitution in the ring system to any extent with alkyl, alkoxy, haloalkyl or halide substituents, whether or not further substituted in the ring system by one or more other univalent substituents;
(ii)
by substitution at the 3–position with an alkyl substituent;
(iii)
by substitution at the 2‑amino nitrogen atom with alkyl or dialkyl groups, or by inclusion of the 2‑amino nitrogen atom in a cyclic structure.”.
Sealed with the Official Seal of the Department of Health, Social Services and Public Safety on 22nd July 2010
These Regulations insert a further group of cathinone derivatives (including naphthylpyrovalerone, commonly known as naphyrone) into Schedule 1 to the Misuse of Drugs Regulations (Northern Ireland) 2002. The schedule in which a controlled drug is placed primarily affects the extent to which the drug can be lawfully imported, exported, produced, supplied or possessed and dictates the record keeping, labelling and destruction requirements in relation to that drug.